Updated

Updated · GamesIndustry.biz · Aug 11

Remedy Q2 Revenue Falls 40% to €10.2 Million as Control Resonant Marketing Lifts Losses

Updated

Updated · GamesIndustry.biz · Aug 11

Remedy Q2 Revenue Falls 40% to €10.2 Million as Control Resonant Marketing Lifts Losses

Q: With revenue plunging, can Remedy's massive gamble on an RPG-style sequel save their ambitious financial goals next month?

Yes—but only if CONTROL Resonant delivers a genuinely strong launch and sustained sales through late 2026 and 2027. Remedy’s revenue slump looks serious on the surface: Q2 sales fell 40% and H1 revenue dropped 23.1%. But the decline was largely caused by a tough comparison with last year’s FBC: Firebreak launch and by heavier marketing spending ahead of Resonant. The more important signal is that the studio still kept full-year guidance unchanged and entered the launch window with €29.6 million in cash and a net cash position of €11.8 million. The gamble is large because Resonant is self-published and more ambitious than the original Control, with broader RPG-style systems and a bigger commercial target. That raises both upside and risk. If the game lands, Remedy captures more of the economics itself, which is crucial to its plan to double 2024 revenue by 2027 and reach a 30% EBITDA margin. There are credible reasons to think the bet can work. Remedy says Resonant has topped 1.5 million wishlists and ranked among the top three PlayStation pre-orders in the US, Germany and Brazil after announcement. Control itself has sold more than 6 million copies over time, and Alan Wake 2 has now passed 3 million, showing Remedy’s franchises can build long tails. But one launch next month will not “save” the whole strategy on its own. Resonant must open well, review well, and keep selling long enough to fund the next wave of projects, including Max Payne 1&2 and Remedy’s unnamed new game.

3 articles · Updated · GamesIndustry.biz · Aug 11

€10.2 million in Q2 revenue and €23.3 million in H1 revenue marked declines of 40% and 23.1%, while Remedy's Q2 operating loss widened to €3.9 million from €0.5 million a year earlier.
Remedy said the drop reflected a tougher comparison with last year's FBC: Firebreak launch and heavier marketing spending ahead of Control Resonant's September 24 release.
Control Resonant pre-orders opened with what the company called healthy momentum, ranking among the top three pre-ordered PlayStation games in the US, Germany and Brazil.
€3.8 million in game sales and royalties fell from €9.5 million a year earlier, though Control sales rose in Q2 and Alan Wake 2 passed 3 million lifetime sales.
Remedy said its catalog and development work on Control Resonant and the Max Payne 1 & 2 remake are supporting the business as it heads toward what it calls its biggest launch yet.